PCVX
Vaxcyte, Inc.
NASDAQ · USHealthcareBiotechnology
$55.50-1.25%
Price as of Jul 20, 2026
PCVX profitability
Vaxcyte, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- —
- EBITDA margin
- —
- EBIT margin
- —
- Net margin
- —
- Free cash flow margin
- —
Returns
- Return on equity
- -31.6%
- Return on assets
- -28.3%
- Return on invested capital
- -35.0%
- Asset turnover
- 0.00x
Cash efficiency
- Cash from operations
- -$769.9M
- Cash per share
- $12
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.